Can Insulet Stock Jump 50%?

PODDYTD-46.4%SPYYTD+11.5%XLVYTD+23.5%
Analyze PODD →

For questions about this article or underlying research, email help@trefis.com.

A 50% jump in Insulet (PODD) stock would depend on the people already using its Omnipod insulin pumps, a group management calls a substantial recurring revenue foundation. A rise that size is not new for this stock, since Insulet shares rose 50% or more from one close to a later close in the same year in eight of the last ten calendar years. Yet the stock fell 54.7% over the twelve months to November 13, 2026, while the S&P 500 returned 11.7%. Insulet’s chance of another jump that size turns on those existing users. So how fast is the number of people using Omnipod still growing?

Image from Pexels

Insulet’s Customer Base Grew More Than 20%

Management said on its November 4, 2026 call that Insulet’s global customer base grew more than 20% from a year earlier in fiscal Q3 2026. New sign-ups grew far more slowly. During the quarter, new customer starts rose only in the low single digits. In the U.S., the customer base grew in the high teens, but new starts were flat.

The financial results reflected the larger customer base. Revenue rose 19.2% to $842 million in the quarter. Management said that the bigger customer base and stable pricing supported that growth. Outside the U.S., Omnipod revenue grew 31.7%, driven primarily by volume, management said.

The prescriber base is growing too. Nearly 34 thousand U.S. health care providers now prescribe Omnipod, up more than 20% year over year.

Slower 2027 Growth Meets A Ten-Year Low Multiple

On the same call, management said 2027 total company growth would come in modestly below the mid-teens framework it gave on its Q2 call, as it takes a more conservative approach, faces a tougher comparison and expects less price mix benefit abroad. Management also expects international growth to moderate meaningfully in 2027.

By the end of September, Insulet’s sales multiple had hit a ten-year low. The stock was priced at 2.8 times sales at September 30, 2026, marking the lowest of the 40 quarter-ends since fiscal Q4 2016. It has since moved up to 3.3 times sales as of November 13. On earnings, though, the stock is not cheap. It trades at 24.7 times trailing profit, against 21.9 for the S&P 500.

Management still expects Insulet to deliver top tier growth on a multi-billion dollar revenue base in 2027 and to further expand profitability. The company is also buying back stock. It plans to spend $400 million on repurchases in the fourth quarter, funded with cash on hand. That spending is equal to about 3.8% of its market value on November 13.

What Would Show Insulet’s Customer Growth Slipping?

More customers leaving Omnipod would be one sign. Type 2 diabetes patients made up over 40% of U.S. new starts in fiscal Q3 2026. Management said retention in that group eroded in the second quarter, with only a modest improvement in the third.

New rivals add to that. Management said on the call that Insulet will lose a couple of share points in new customer starts as competitors come in, while its own Omnipod 6 is expected to launch in 2027.

A holder should also know how hard the shares can fall. During the 2023 bond yield shock, from July to December 2023, Insulet stock fell as much as 55.0% at its lowest close, while the S&P 500 ETF fell as much as 9.5% at its lowest close.

Growth in Insulet’s global customer base is the number to watch when the company reports fiscal Q4 2026 results. Those results are expected in February 2027, on the call where management plans to give formal 2027 guidance.

Want A Second Look At What You Own?

Insulet is one decision in a portfolio. Whether you work with an advisor or manage your money yourself, a second look at the whole portfolio costs nothing. Our partner advisory firm offers a free written review of your holdings, fees and income plan, with no need to switch.

Get A Free Second Opinion

Spot an error or want more like this? Tell us in 10 seconds.